Evoco promotes Sormani to partner

Harriet Matthews
14 March 2022

Tweet
Facebook
LinkedIn
Google plus
Send to

Switzerland-headquartered specialised portfolio investor Evoco has announced the promotion of Lorenzo Gregory Sormani to partner.

Sormani joined the firm in 2016, bringing experience from his role at McKinsey & Company, where he provided commercial due diligence advice to European mid-cap private equity clients.

The GP said in a statement that Sormani has made significant contributions to Evoco and its portfolio across the investment life cycle, as well as having a meaningful impact on the firm's investment strategy.

Following the promotion, Sormani is expected to continue his portfolio and deal execution roles, as well as heading talent acquisition and human resources initiatives, Evoco said in the same statement.

Michel Galeazzi and Felix Ackermann co-founded Evoco in 2012. The firm now has an investment team of three partners, as well as two directors, one associate director and four associates.

Following Sormani's promotion, the team expects to hire another director and is also looking to hire an analyst.

"Evoco's growth story and differentiated strategy are exciting for potential candidates," a spokesperson for Evoco told Unquote. "The market is dynamic, and DACH is a very attractive market. We are looking at a pan-European market for hiring, including German-speakers in London or even the Nordics."

Evoco is currently deploying equity via Evoco TSE III, which held a final close in January 2022 on EUR 162m. Evoco specialises in the acquisition of groups of non-core assets via portfolio transactions, targeting lower-mid-market businesses with turnovers of EUR 30m-EUR 250m, according to Unquote Data. Evoco TSE III deploy equity tickets of EUR 20m-EUR 75m, with a sweet spot of EUR 40m. The GP invests in western Europe, with a focus on the DACH region.

Evoco TSE III has made two portfolio deals to date and is expected to make three in total. It announced its latest acquisition in February, as reported, acquiring three Austria-based companies including medical technology company the Agency for Medical Innovations (AMI).